Likewise, a recent study of the ADNI cohort found that CSF VILIP-1 levels at baseline were higher in Alzheimer’s disease patients and mild cognitive impaired individuals with amyloid-β positivity compared with cognitively normal (Aβ-negative) and amyloid-β-negative mild cognitive-impaired persons [190]. This evidence concerns the gene VSNL1 and Alzheimer disease.